Head to Head Survey: Perspective Therapeutics (NYSE:CATX) & Titan Medical (NASDAQ:TMDIF)

Perspective Therapeutics (NYSE:CATX) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Profitability

This table compares Perspective Therapeutics and Titan Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Perspective Therapeutics	-4,096.66%	-27.40%	-23.16%
Titan Medical	N/A	-82.31%	-51.47%

Valuation & Earnings

This table compares Perspective Therapeutics and Titan Medical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perspective Therapeutics	$1.43 million	139.91	-$46.51 million	N/A	N/A
Titan Medical	$17.63 million	2.27	$6.95 million	$0.05	7.02

Titan Medical has higher revenue and earnings than Perspective Therapeutics.

Risk & Volatility

Perspective Therapeutics has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Titan Medical has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Perspective Therapeutics and Titan Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perspective Therapeutics	0	1	7	1	3.00
Titan Medical	0	0	0	0	0.00

Perspective Therapeutics presently has a consensus price target of $15.14, suggesting a potential upside of 411.58%. Given Perspective Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Perspective Therapeutics is more favorable than Titan Medical.

Insider and Institutional Ownership

54.7% of Perspective Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Titan Medical shares are owned by institutional investors. 3.5% of Perspective Therapeutics shares are owned by insiders. Comparatively, 0.0% of Titan Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Perspective Therapeutics beats Titan Medical on 9 of the 13 factors compared between the two stocks.

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

About Titan Medical

Titan Medical Inc. operates as a medical technology company. It focuses on the development and licensing of robotic assisted surgical technologies. The company is headquartered in Toronto, Canada.